27
Participants
Start Date
June 30, 2014
Primary Completion Date
April 2, 2019
Study Completion Date
April 26, 2022
Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
The Ohio State University, Columbus
Medical College of Wisconsin, Milwaukee
University of Minnesota, Minneapolis
Versiti
OTHER
Ohio State University
OTHER
Medical College of Wisconsin
OTHER